|
1
|
A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs.
|
Antimicrob Agents Chemother
|
1998
|
5.64
|
|
2
|
Performance of the Affymetrix GeneChip HIV PRT 440 platform for antiretroviral drug resistance genotyping of human immunodeficiency virus type 1 clades and viral isolates with length polymorphisms.
|
J Clin Microbiol
|
1999
|
2.51
|
|
3
|
Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro.
|
J Virol
|
1998
|
2.50
|
|
4
|
High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients.
|
J Clin Microbiol
|
2001
|
2.45
|
|
5
|
Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples.
|
AIDS
|
2000
|
2.15
|
|
6
|
A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance.
|
Antimicrob Agents Chemother
|
1999
|
2.08
|
|
7
|
Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility.
|
J Virol
|
1996
|
2.03
|
|
8
|
A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidine.
|
J Virol
|
1998
|
1.92
|
|
9
|
Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting.
|
AIDS
|
1999
|
1.85
|
|
10
|
A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V.
|
Antimicrob Agents Chemother
|
2000
|
1.75
|
|
11
|
An in vitro model of angiogenesis: basic features.
|
Angiogenesis
|
1999
|
1.71
|
|
12
|
Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naïve HIV-1 infected US military personnel.
|
AIDS
|
2000
|
1.53
|
|
13
|
Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples.
|
AIDS
|
2000
|
1.43
|
|
14
|
Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group.
|
J Infect Dis
|
2000
|
1.37
|
|
15
|
Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failure.
|
J Infect Dis
|
1998
|
1.26
|
|
16
|
Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure.
|
AIDS
|
2000
|
1.23
|
|
17
|
The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
|
AIDS
|
1998
|
1.11
|
|
18
|
Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen.
|
AIDS
|
2000
|
1.10
|
|
19
|
Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group.
|
J Virol
|
1996
|
1.08
|
|
20
|
HIV drug susceptibility and treatment response to mega-HAART regimen in patients from the Frankfurt HIV cohort.
|
Antivir Ther
|
2000
|
1.01
|
|
21
|
Variable relationship between proviral DNA load and infectious virus titre in the peripheral blood mononuclear cells of HIV-1-infected individuals.
|
AIDS
|
1993
|
0.97
|
|
22
|
Despite high concordance, distinct mutational and phenotypic drug resistance profiles in human immunodeficiency virus type 1 RNA are observed in gastrointestinal mucosal biopsy specimens and peripheral blood mononuclear cells compared with plasma.
|
J Infect Dis
|
2000
|
0.92
|
|
23
|
Resistance to antiretroviral therapy among patients in Uganda.
|
J Acquir Immune Defic Syndr
|
2001
|
0.91
|
|
24
|
Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus.
|
Gut
|
2001
|
0.88
|
|
25
|
The rabbit study: ritonavir and saquinavir in combination in saquinavir-experienced and previously untreated patients.
|
AIDS Res Hum Retroviruses
|
1999
|
0.76
|
|
26
|
Prevalence of HIV-1 drug resistance in antiretroviral-naive patients: a prospective study.
|
AIDS
|
2001
|
0.76
|
|
27
|
Development of a rapid quantitative assay for HIV-1 plasma infectious viraemia-culture-PCR (CPID).
|
J Med Virol
|
1994
|
0.75
|